Earnings Feed
Start Free
Home/Filings/4/0000899243-20-015630
4//SEC Filing

Flagship Ventures Fund IV General Partner LLC 4

Accession 0000899243-20-015630

CIK 0001751299other
View on SEC.govCompany Profile

Filed

Jun 7, 8:00 PM ET

Accepted

Jun 8, 4:46 PM ET

Size

25.6 KB

Accession

0000899243-20-015630

Insider Transaction Report

Form 4
Period: 2020-06-04
Kaleido Biosciences, Inc.KLDO
Flagship Ventures Fund IV General Partner LLC
Director10% Owner
Transactions
  • Purchase

    Common Stock

    2020-06-04$7.50/sh+666,667$5,000,003→ 1,613,778 total(indirect: See Footnote)
  • Purchase

    Common Stock

    2020-06-04$7.50/sh+666,667$5,000,003→ 2,910,972 total(indirect: See Footnote)
  • Purchase

    Common Stock

    2020-06-04$7.50/sh+666,666$4,999,995→ 666,666 total(indirect: See Footnote)
Holdings

  • Common Stock

    (indirect: See Footnote)
    639,360

  • Common Stock

    (indirect: See Footnote)
    2,560,096

  • Common Stock

    (indirect: See Footnote)
    216,451

  • Common Stock

    (indirect: See Footnote)
    42,865

  • Common Stock

    (indirect: See Footnote)
    1,649,999

  • Common Stock

    (indirect: See Footnote)
    2,500,000

  • Common Stock

    (indirect: See Footnote)
    6,560,523
Flagship Ventures Opportunities Fund I General Partner LLC
10% Owner
Transactions
  • Purchase

    Common Stock

    2020-06-04$7.50/sh+666,666$4,999,995→ 666,666 total(indirect: See Footnote)
  • Purchase

    Common Stock

    2020-06-04$7.50/sh+666,667$5,000,003→ 2,910,972 total(indirect: See Footnote)
  • Purchase

    Common Stock

    2020-06-04$7.50/sh+666,667$5,000,003→ 1,613,778 total(indirect: See Footnote)
Holdings

  • Common Stock

    (indirect: See Footnote)
    42,865

  • Common Stock

    (indirect: See Footnote)
    639,360

  • Common Stock

    (indirect: See Footnote)
    2,560,096

  • Common Stock

    (indirect: See Footnote)
    1,649,999

  • Common Stock

    (indirect: See Footnote)
    2,500,000

  • Common Stock

    (indirect: See Footnote)
    6,560,523

  • Common Stock

    (indirect: See Footnote)
    216,451
Flagship Ventures Opportunities Fund I, L.P.
10% Owner
Transactions
  • Purchase

    Common Stock

    2020-06-04$7.50/sh+666,667$5,000,003→ 1,613,778 total(indirect: See Footnote)
  • Purchase

    Common Stock

    2020-06-04$7.50/sh+666,666$4,999,995→ 666,666 total(indirect: See Footnote)
  • Purchase

    Common Stock

    2020-06-04$7.50/sh+666,667$5,000,003→ 2,910,972 total(indirect: See Footnote)
Holdings

  • Common Stock

    (indirect: See Footnote)
    42,865

  • Common Stock

    (indirect: See Footnote)
    2,500,000

  • Common Stock

    (indirect: See Footnote)
    6,560,523

  • Common Stock

    (indirect: See Footnote)
    1,649,999

  • Common Stock

    (indirect: See Footnote)
    216,451

  • Common Stock

    (indirect: See Footnote)
    2,560,096

  • Common Stock

    (indirect: See Footnote)
    639,360
AFEYAN NOUBAR
Director10% Owner
Transactions
  • Purchase

    Common Stock

    2020-06-04$7.50/sh+666,666$4,999,995→ 666,666 total(indirect: See Footnote)
  • Purchase

    Common Stock

    2020-06-04$7.50/sh+666,667$5,000,003→ 1,613,778 total(indirect: See Footnote)
  • Purchase

    Common Stock

    2020-06-04$7.50/sh+666,667$5,000,003→ 2,910,972 total(indirect: See Footnote)
Holdings

  • Common Stock

    (indirect: See Footnote)
    2,500,000

  • Common Stock

    (indirect: See Footnote)
    639,360

  • Common Stock

    (indirect: See Footnote)
    216,451

  • Common Stock

    (indirect: See Footnote)
    42,865

  • Common Stock

    (indirect: See Footnote)
    2,560,096

  • Common Stock

    (indirect: See Footnote)
    6,560,523

  • Common Stock

    (indirect: See Footnote)
    1,649,999
Flagship Ventures Fund IV, L.P.
10% Owner
Transactions
  • Purchase

    Common Stock

    2020-06-04$7.50/sh+666,667$5,000,003→ 1,613,778 total(indirect: See Footnote)
  • Purchase

    Common Stock

    2020-06-04$7.50/sh+666,666$4,999,995→ 666,666 total(indirect: See Footnote)
  • Purchase

    Common Stock

    2020-06-04$7.50/sh+666,667$5,000,003→ 2,910,972 total(indirect: See Footnote)
Holdings

  • Common Stock

    (indirect: See Footnote)
    6,560,523

  • Common Stock

    (indirect: See Footnote)
    1,649,999

  • Common Stock

    (indirect: See Footnote)
    42,865

  • Common Stock

    (indirect: See Footnote)
    2,500,000

  • Common Stock

    (indirect: See Footnote)
    2,560,096

  • Common Stock

    (indirect: See Footnote)
    216,451

  • Common Stock

    (indirect: See Footnote)
    639,360
Footnotes (13)
  • [F1]On June 4, 2020, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") acquired 666,667 shares pursuant to an underwritten public offering of common stock by the Issuer (the "Offering").
  • [F10]Shares held by Nutritional Health Side Fund, L.P. ("Nutritional Health Side Fund"). Flagship Fund V GP is the general partner of Nutritional Health Side Fund. Dr. Afeyan serves as sole manager of Flagship Fund V GP. Each of the reporting persons except for Nutritional Health Side Fund disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
  • [F11]Shares held by Nutritional Health Disruptive Innovation Fund, L.P. ("Nutritional Innovation Fund"). Flagship Fund V GP is the general partner of Nutritional Innovation Fund. Dr. Afeyan serves as sole manager of Flagship Fund V GP. Each of the reporting persons except for Nutritional Innovation Fund disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
  • [F12]Shares held by Flagship Ventures Fund 2007, L.P. ("Flagship Fund 2007"). Flagship Ventures 2007 General Partner LLC ("Fund 2007 GP") is the general partner of Flagship Fund 2007. Dr. Afeyan is the sole manager of Fund 2007 GP. Each of the reporting persons except for Flagship Fund 2007 disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Edwin M. Kania, Jr. is retired both from Flagship Pioneering and as a manager of Fund 2007 GP.
  • [F13]Shares held by Cadena LLC ("Cadena"). Dr. Afeyan is the sole manager of Cadena. Each of the reporting persons except for Cadena disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
  • [F2]Shares held by Flagship Fund IV. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Edwin M. Kania, Jr. is retired both from Flagship Pioneering, Inc. ("Flagship Pioneering") and as a manager of Flagship Fund IV GP.
  • [F3]On June 4, 2020, Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I") acquired 666,667 shares pursuant to the Offering.
  • [F4]Shares held by Flagship Opportunities I. Flagship Ventures Opportunities Fund I General Partner LLC ("Flagship Opportunities GP") is the general partner of Flagship Opportunities I. Dr. Afeyan serves as sole manager of Flagship Opportunities GP. Each of the reporting persons except for Flagship Opportunities I disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
  • [F5]On June 4, 2020, Nutritional Health LTP Fund, L.P. ("Nutritional LTP") acquired 666,666 shares pursuant to the Offering.
  • [F6]Shares held by Nutritional LTP. Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP") is the general partner of Nutritional LTP. Dr. Afeyan is the sole member and manager of Nutritional LTP GP. Each of the reporting persons except for Nutritional LTP disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
  • [F7]Shares held by Flagship VentureLabs IV, LLC ("VentureLabs IV"). Flagship Fund IV is a member of VentureLabs IV and also serves as its manager. Flagship Fund IV GP is the general partner of Flagship Fund IV. Dr. Afeyan is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for VentureLabs IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
  • [F8]Shares held by Flagship VentureLabs V LLC ("VentureLabs V"). Flagship Ventures Fund V, L.P. ("Flagship Fund V") is a member of VentureLabs V. Flagship Ventures Fund V General Partner LLC ("Flagship Fund V GP") is the general partner of Flagship Fund V. Flagship VentureLabs V Manager LLC ("VentureLabs V Manager") serves as manager of VentureLabs V. Flagship Pioneering is the manager of VentureLabs V Manager. Dr. Afeyan serves as sole manager of Flagship Fund V GP and as sole director of Flagship Pioneering. Each of the reporting persons except for VentureLabs V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
  • [F9]Shares held by Flagship Fund V. Flagship Fund V GP is the general partner of Flagship Fund V. Dr. Afeyan serves as sole manager of Flagship Fund V. Each of the reporting persons except for Flagship Fund V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

Documents

1 file

Issuer

Kaleido Biosciences, Inc.

CIK 0001751299

→
Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001508051

Filing Metadata

Form type
4
Filed
Jun 7, 8:00 PM ET
Accepted
Jun 8, 4:46 PM ET
Size
25.6 KB
View on SEC.gov